Výsledky vyhledávání - "N. Martin Lunde"

Comparative efficacy and tolerability of two long-acting calcium antagonists, mibefradil and amlodipine, in essential hypertension

Autor: N. Martin Lunde, Joan Ryder Benz, Thomas Marbury, Fred E. Karch, James N. Tarro, Albert A. Carr, Robert Pordy

Publikováno v: Clinical Therapeutics. 19:1368-1378

In a previous forced-titration trial, mibefradil 100 mg QD was as effective as amlodipine 10 mg QD in reducing sitting diastolic blood pressure (SDBP), and it produced significantly less leg edema than did amlodipine 10 mg QD. The present multicenter

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cfa26319c793cbc1b674e049e0697e4a
https://doi.org/10.1016/s0149-2918(97)80011-2

Zobrazit plný text záznamu

Pharmacokinetics of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, in patients with moderate hepatic impairment

Autor: Ajay Nirula, Kenneth C. Lasseter, Eseng Lai, Ying-Hong Wang, Julie Ann Mabalot Luk, Amy O. Johnson-Levonas, Thomas Marbury, N. Martin Lunde, John A. Wagner, Fang Liu

Publikováno v: Journal of clinical pharmacology. 51(3)

This open-label study evaluated the influence of hepatic insufficiency on the pharmacokinetics of laropiprant (LRPT), a prostaglandin D 2 receptor-1 antagonist, to guide clinicians in the event of inadvertent dosing in patients with hepatic insuffici

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b45aad90887da53a468580dd71fed0c6
https://pubmed.ncbi.nlm.nih.gov/20484612

Zobrazit plný text záznamu

Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease

Autor: Frank C. Dougherty, Steven Fishbane, Moro O. Salifu, Vinod Bansal, N. Martin Lunde, Ulrich Beyer, Anatole Besarab

Publikováno v: Clinical therapeutics. 29(4)

A continuous erythropoietin receptor activator (C.E.R.A.) is currently in development for the treatment of anemia in patients with chronic renal disease (CRD) receiving or not receiving dialysis treatment.The objectives of this study were to determin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2ab910982b18e915c78cfee7cf137ab
https://pubmed.ncbi.nlm.nih.gov/17617286

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání